公司公告汇总 北京赛科希德科技股份有限公司发布2025年度业绩快报，营业总收入为263,667,956.92元，同比下降 13.80%；归属于母公司所有者的净利润为87,143,189.53元，同比下降22.88%。扣除非经常性损益后的净 利润同比下降26.31%。总资产为1,765,953,055.92元，较期初增长0.99%；归属于母公司的所有者权益增 长2.50%。业绩下滑主要受体外诊断行业医保控费政策影响，市场需求减少，试剂收入下降导致利润降 幅大于收入降幅。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自业绩披露要点：赛科希德2025年归属净利润同比下降22.88%。 来自公司公告汇总：营业总收入为263,667,956.92元，同比下降13.80%。 来自业绩披露要点：业绩下滑主因医保控费致试剂收入下降。 来自公司公告汇总：扣非后净利润同比下降26.31%，资产总额较期初增0.99%。 截至2026年1月30日收盘，赛科希德（688338）报收于29.04元，较上周的28.99元上涨0.17%。本周，赛 科希德1月 ...

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [13]. Core Insights - The company has been deeply engaged in the in vitro diagnostics field for thirty years, establishing a comprehensive product matrix of instruments and reagents with excellent performance. It has expanded horizontally into molecular diagnostics and biochemical diagnostics, solidifying its competitive advantage as a leader in chemiluminescence [3]. - As a pioneer in the overseas expansion of chemiluminescence, the company has seen rapid growth in overseas installations and revenue, exporting to 167 countries and establishing 14 overseas subsidiaries to enhance local operational capabilities. The report anticipates a performance acceleration phase in the next 3-5 years due to increasing domestic localization rates and faster entry into core hospitals and markets abroad [3]. Summary by Relevant Sections Chemiluminescence: Domestic and Overseas Growth - The global immunodiagnostics market is expected to grow from $18.9 billion in 2019 to $27.7 billion by 2024, with a compound annual growth rate (CAGR) of 8.0%. The Chinese market is projected to grow at a CAGR of 11.4% during the same period [8][33]. - In China, the market is expected to recover in 2026 after experiencing a decline in 2025 due to price reductions from centralized procurement and adjustments in value-added tax [8][41]. - The localization rate for chemiluminescence products has room for improvement, with over 70% already under centralized procurement. The localization rates for various categories are 66% for sex hormones, 59% for thyroid function, 53% for tumor markers, and 52% for glucose metabolism [8][47]. Product Performance and Market Share - The company maintains industry-leading product capabilities, with a coverage rate in top-tier hospitals increasing to 61%. It has developed a full range of products, including 12 models of instruments sold globally by mid-2025 [10]. - The innovative detection method has optimized reagent performance, achieving significant improvements in sensitivity and accuracy. The company’s market share in tumor markers and thyroid function projects is expected to grow significantly [10][84]. Overseas Market Localization and Growth - The company has established 14 overseas branches, focusing on localized operations. For example, in India, the company has built a robust agent network, with revenue expected to exceed 200 million yuan by 2024 [11]. - The overseas reagent segment is anticipated to be a significant growth driver, with overseas reagent revenue projected to reach 57% by 2024, compared to 80% in the domestic market [11]. Profit Forecast - The company is expected to achieve net profits of 1.65 billion yuan, 2.0 billion yuan, and 2.41 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings ratios of 26X, 21X, and 18X [11].

Group 1 - The Nipah virus outbreak in India has raised concerns, particularly in West Bengal, but its impact on China is considered minimal as no cases have been reported in the country [1] - The market has shown increased interest in stocks related to virus prevention and diagnostics, with companies like Capbio and Da'an Gene experiencing significant stock price increases [1] - The Nipah virus has a transmission period of 3 to 14 days, with initial symptoms resembling influenza, making early detection crucial for effective intervention [1] Group 2 - Several A-share listed companies have announced their developments in Nipah virus detection technologies, including Wanfu Bio and Shengxiang Bio, which have launched various testing kits [3][5] - Capbio has developed a Nipah virus nucleic acid detection kit, providing essential support for global quarantine and disease control monitoring [5] - Some companies, such as Hualan Vaccine and Yirui Bio, have clarified that they do not have any products related to Nipah virus prevention or treatment [5][6]

Group 1 - The Nipah virus outbreak in India has raised attention, particularly in the stock market, with related concept stocks experiencing significant gains. Companies like Capbio and Da'an Gene have seen consecutive price increases [2] - The Nipah virus primarily spreads through direct contact with infected animals, patients, and contaminated materials, with a low survival rate in the environment. The outbreak is mainly concentrated in West Bengal, India, which does not border China, minimizing the impact on China [2] - Early detection of the Nipah virus is crucial for clinical intervention and public health measures, as the incubation period ranges from 3 to 14 days, and initial symptoms resemble those of influenza [2] Group 2 - Several A-share listed companies have disclosed their technology and product layouts related to Nipah virus testing. For instance, Wanfu Bio has launched various forms of Nipah virus nucleic acid test kits compatible with their molecular POCT platform [4] - Shengxiang Bio has actively engaged with local health authorities in India to address the outbreak, developing corresponding detection solutions based on their fluorescence PCR technology [4] - Capbio has developed a nucleic acid test kit for the Nipah virus, providing essential technical support for global quarantine and disease control monitoring [6] Group 3 - Some A-share companies have clarified their positions regarding the Nipah virus, stating they do not have relevant business layouts. For example, Hualan Biological announced that it primarily manufactures human vaccines and does not have products for Nipah virus prevention [7] - Other companies like Yirui Bio, Renhe Pharmaceutical, and CanSino have also confirmed through investor interactions that they do not have related products [7]

Core Viewpoint - The stock of Capbio has experienced a consecutive two-day limit-up, indicating strong market interest, particularly due to recent Nipah virus infection cases in Eastern India, which aligns with the company's product offerings in virus detection [1] Group 1: Stock Performance - Capbio's stock reached a limit-up at 13:08 today, with a trading volume of 1.275 billion yuan and a turnover rate of 24.53% [1] Group 2: Product and Market Position - The company possesses Nipah virus nucleic acid test kits, which are relevant for epidemic monitoring and border control [1] - As a leading integrated supplier of molecular diagnostic products and services in China, Capbio has developed products for infectious disease testing, covering clinical diagnosis in hospitals and public health prevention [1] Group 3: Research and Development - Capbio is advancing clinical research on HPV infection treatment, with international product deployment across multiple countries and regions [1] - The diversification of the company's business may enhance market attention and support its operations [1] Group 4: Market Trends - The virus prevention concept sector is gaining market attention, and changes in related demand may provide support for the company's business [1]

Market Overview - The A-share market saw most indices decline today, with the Shanghai Composite Index slightly down by 0.09% closing at 4132.61 points, the Shenzhen Component Index down by 0.85% at 14316.64 points, the ChiNext Index down by 0.91% at 3319.15 points, and the STAR 50 Index down by 1.35% at 1532.8 points [1] - Overall, there were 1602 stocks that rose and 3767 stocks that fell, with a total trading volume of 32,482 billion yuan, an increase of 1630 billion yuan compared to the previous trading day [1] Industry Performance - Among the primary industries, non-ferrous metals, petroleum and petrochemicals, coal, agriculture, forestry, animal husbandry, and fishery led the gains with increases of 4.57%, 3.18%, 2.07%, 0.85%, and 0.79% respectively [1] - Conversely, industries such as defense and military, automotive, social services, electronics, and real estate experienced declines, with decreases of 4.47%, 2.31%, 2.30%, 2.24%, and 2.23% respectively [1] Concept Sector Performance - The top-performing concept sectors included gold and jewelry, vaccines, selected rare metals, animal health, blood products, industrial metals, nickel ore, rare earths, influenza, cobalt ore, small metals, and biotechnology [2] - Sectors such as satellite internet, commercial aerospace, satellite navigation, and military information technology experienced pullbacks [2]

Core Viewpoint - The company, New Industry Biomedical Engineering Co., Ltd., has experienced a decline in stock price and a mixed financial performance, with a slight increase in revenue but a significant decrease in net profit [1][2]. Group 1: Stock Performance - On January 20, the stock price of New Industry fell by 2.05% to 56.76 CNY per share, with a trading volume of 112 million CNY and a turnover rate of 0.29%, resulting in a total market capitalization of 44.597 billion CNY [1]. - Year-to-date, the stock price has increased by 0.91%, but it has decreased by 4.96% over the last five trading days, 3.80% over the last 20 days, and 8.32% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 3.428 billion CNY, representing a year-on-year growth of 0.39%, while the net profit attributable to shareholders was 1.205 billion CNY, reflecting a year-on-year decrease of 12.92% [2]. - Cumulatively, since its A-share listing, the company has distributed a total of 3.86 billion CNY in dividends, with 2.357 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 15.87% to 13,100, with an average of 51,997 circulating shares per shareholder, which is an increase of 18.87% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 26.4824 million shares, an increase of 4.2383 million shares from the previous period [3].

Group 1 - The core viewpoint of the news is that Aihuilong's stock has experienced fluctuations, with a recent decline in price and significant changes in trading volume and shareholder structure [1][2]. - As of January 16, Aihuilong's stock price was 15.05 yuan per share, with a market capitalization of 8.599 billion yuan and a trading volume of 55.8934 million yuan [1]. - The company has seen a year-to-date stock price increase of 5.99%, but a decline of 3.77% over the last five trading days [1]. Group 2 - Aihuilong's main business involves the research, production, and sales of in vitro diagnostic instruments and related reagents, with a revenue composition of 58.57% from self-produced reagents (non-COVID products) [1]. - As of September 30, the company reported a revenue of 1.287 billion yuan for the first nine months of 2025, a year-on-year decrease of 7.69%, and a net profit of 60.4209 million yuan, down 72.36% year-on-year [2]. - The company has distributed a total of 693 million yuan in dividends since its A-share listing, with 531 million yuan distributed over the past three years [3].

Core Viewpoint - Mindray Medical experienced a stock price decline of 2.00% on January 15, 2023, with a trading price of 203.60 CNY per share and a total market capitalization of 246.85 billion CNY [1] Group 1: Stock Performance - Year-to-date, Mindray Medical's stock price has increased by 6.90%, with a 0.94% rise over the last five trading days and a 4.51% increase over the last 20 days, while it has decreased by 8.38% over the last 60 days [1] - As of September 30, 2025, Mindray Medical reported a total revenue of 25.83 billion CNY, a year-on-year decrease of 12.38%, and a net profit attributable to shareholders of 7.57 billion CNY, down 28.83% year-on-year [2] Group 2: Financials and Shareholder Information - Since its A-share listing, Mindray Medical has distributed a total of 35.34 billion CNY in dividends, with 25.03 billion CNY distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for Mindray Medical reached 108,800, an increase of 18.86% from the previous period, while the average circulating shares per person decreased by 15.87% to 11,139 shares [2]

Core Viewpoint - Shengxiang Bio's stock price has shown fluctuations, with a recent decline of 2.04% and a total market value of 11.663 billion yuan, while the company has experienced a year-to-date stock price increase of 6.45% [1] Financial Performance - For the period from January to September 2025, Shengxiang Bio achieved operating revenue of 1.244 billion yuan, representing a year-on-year growth of 20.49%, while the net profit attributable to shareholders decreased by 2.10% to 191 million yuan [2] - Cumulatively, since its A-share listing, Shengxiang Bio has distributed a total of 2.363 billion yuan in dividends, with 967 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Shengxiang Bio increased by 4.17% to 21,600, with an average of 26,772 circulating shares per person, which is a decrease of 4.01% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 9.8053 million shares, a decrease of 1.7872 million shares compared to the previous period, while Hong Kong Central Clearing Limited is a new shareholder with 3.6601 million shares [3] Business Overview - Shengxiang Bio, established on April 23, 2008, and listed on August 28, 2020, focuses on innovative gene technology, encompassing the research, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services [1] - The company's main revenue sources include diagnostic reagents (87.39%), diagnostic instruments (5.71%), testing services (4.55%), and other supplementary services (2.34%) [1]